Overview


According to FutureWise analysis the Interventional Oncology  Market in 2025 is US$ 2.85 billion, and is expected to reach US$ 5.03 billion by 2033 at a CAGR of 7.36%. The rising global cancer rates and the increasing demand for less invasive treatments are driving the growth of interventional oncology.This area is becoming crucial for cancer treatment, providing targeted therapies that usually lead to quicker recovery periods and reduced side effects compared to conventional methods, backed by improvements in imaging-guided therapies.

Interventional oncology represents a dynamic subspecialty within interventional radiology dedicated to the diagnosis, treatment, and management of cancers through minimally invasive, image-guided procedures. This innovative field merges advanced imaging technologies with precise therapeutic techniques, enabling healthcare professionals to target tumors effectively while minimizing harm to surrounding healthy tissues. As a result, interventional oncology has significantly transformed cancer care by providing less invasive alternatives to traditional surgical approaches, leading to shorter recovery periods, fewer complications, and enhanced quality of life for patients.

Various interventional oncology procedures include ablation techniques, such as radiofrequency, microwave, and cryoablation, which focus on destroying tumors using heat or cold. Additionally, embolization therapies like transarterial chemoembolization and radioembolization are employed to obstruct a tumor’s blood supply or to deliver localized chemotherapy or radiation. Image-guided biopsies are also utilized for precise cancer diagnosis. These procedures are applicable to various cancers affecting the liver, lung, kidney, bone, and other organs, particularly among patients who may not be suitable candidates for conventional surgery due to advanced disease states or additional health conditions.

The discipline utilizes cutting-edge imaging modalities—such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound—to ensure high precision during interventions. This technological capability enables interventional oncologists to accurately target tumors as small as a few millimeters while preserving healthy tissue. Interventional oncology is often incorporated into multidisciplinary cancer treatment plans, complementing surgical interventions, chemotherapy, and radiation therapy. Furthermore, it holds significant value in palliative care, particularly in alleviating symptoms like pain or obstruction in patients with advanced cancer.

Recent advancements in the field, including robotic guidance, artificial intelligence, and the development of novel embolic agents, are enhancing the precision and effectiveness of interventional oncology. As the field continues to grow, it is propelled by technological innovations and an expanding body of research that underscores its importance in personalized cancer treatment. By offering targeted, less invasive options, interventional oncology empowers patients with increased choices in their care. Ultimately, it plays a crucial role in the evolving landscape of oncology, effectively bridging the gap between diagnostic processes and therapeutic interventions.

The market is regionally fragmented into North America, Europe, Asia Pacific, Latin America and Middle East, Africa. The European and North American regions are expected to showcase significant market growth over the forecast period owing to an increasing cancer patient population. Furthermore, well-established health care infrastructure, effective cancer management, increasing adoption of minimally invasive surgical procedures are some of the key factors responsible for the proliferation of the market.

Global Conferences: Events such as the European Conference on Interventional Oncology (ECIO) 2025 and the Symposium on Clinical Interventional Oncology (CIO) 2025 provide platforms for sharing knowledge and advancements in the field.

  • Medtronic
  • Boston Scientific
  • BTG Plc.
  • Terumo
  • Merit Medical
  • Sirtex
  • Ethicon
  • Cook Medical
  • Teleflex
  • HealthTronics
  • MedWaves Medical
  • IceCure Medical
  • Interface Biomaterial BV
  • Mermaid Medicals
  • ABK Biomedical
  • Guerbet
  • Endo Shape
  • Instylla
  • Shape Memory Medical
  • Monteris Medical
  • Trisalus Lifesciences

(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent developments by key players in Interventional Oncology Market:

Sirtex

In July 2025, the U.S. Food and Drug Administration (FDA) approved SIR-Spheres® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC). This approval makes it the only radioembolization therapy in the United States that is authorized for both metastatic colorectal cancer (mCRC) and HCC.

Boston Scientific

  • Acquisition of Intera Oncology (Nov 2024): Integrated the Intera 3000 Hepatic Artery Infusion Pump and floxuridine, enhancing treatment options for liver metastases.
  • Boston Scientific offers a variety of interventional oncology and embolization products, including Y-90 microspheres, coils, beads, and cryoablation systems. Their goal is to provide targeted treatments that improve the lives of patients facing cancer and other serious diseases.

Medtronic

  • AI-powered ablation technologies: Advancing leadership in ablation through innovative imaging and AI tools, with a significant emphasis on the Asia-Pacific region.
  • Pulsed-field systems achievement: Its interventional oncology ablation segment achieved US $1 billion in FY25, reflecting approximately 30% year-over-year growth.

By Product

  • Embolization Devices
    • Radioembolic Agents
    • Non-Radioactive Embolic Agents
  • Ablation Devices
    • Radiofrequency Ablation Devices
    • Microwave Ablation Devices
    • Cryoablation Devices
    • Other Ablation Devices
  • Support Devices
    • Microcatheters
    • Guidewires

By Procedure

  • Thermal Tumour Ablation
  • Non-thermal Tumour Ablation
  • Transcatheter Arterial Chemoembolization
  • Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
  • Transcatheter Arterial Embolization/Bland Embolization

By Cancer Type

  • Liver Cancer
  • Lung Cancer
  • Bone Cancer
  • Kidney Cancer
  • Other Cancers

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects for market
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the market by product, by procedure, by cancer type and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East
  • Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Interventional Oncology Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Interventional Oncology Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Interventional Oncology Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Interventional Oncology Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Interventional Oncology Market, By Product Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Embolization Devices
         1.1. Radioembolic Agents
         1.2. Non-Radioactive Embolic Agents
        2. Ablation Devices
         2.1. Radiofrequency Ablation Devices
         2.2. Microwave Ablation Devices
         2.3. Cryoablation Devices
         2.4. Other Ablation Devices
        3. Support Devices
         3.1. Microcatheters
         3.2. Guidewires

  • 8.   Interventional Oncology Market, By Procedure Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Thermal Tumour Ablation
        2. Non-thermal Tumour Ablation
        3. Transcatheter Arterial Chemoembolization
        4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
        5. Transcatheter Arterial Embolization/Bland Embolization

  • 9.   Interventional Oncology Market, By Cancer Type Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Liver Cancer
        2. Lung Cancer
        3. Bone Cancer
        4. Kidney Cancer
        5. Other Cancers

  • 10.   North America Interventional Oncology Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 11.   Latin America Interventional Oncology Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 12.   Europe Interventional Oncology Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 13.   Asia Pacific Interventional Oncology Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Taiwan
         2.9. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 14.   Middle East and Africa Interventional Oncology Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    •   1. Medtronic
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Boston Scientific
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. BTG Plc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Terumo
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5 . Merit Medical
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6 . Sirtex
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Ethicon
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Cook Medical
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Teleflex
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. HealthTronics
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. MedWaves Medical
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. IceCure Medical
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Interface Biomaterial BV
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Mermaid Medicals
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. ABK Biomedical
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Guerbet
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Endo Shape
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Instylla
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Shape Memory Medical
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Monteris Medical
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Trisalus Lifesciences
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

FAQ


Interventional oncology is a medical specialty that utilizes image-guided, minimally invasive procedures for diagnosing and treating cancer. These procedures commonly include targeted therapies such as ablation, embolization, and localized drug delivery directly to tumors.

Interventional oncology is a medical specialty that utilizes image-guided, minimally invasive procedures for diagnosing and treating cancer. These procedures commonly include targeted therapies such as ablation, embolization, and localized drug delivery directly to tumors.

Interventional oncology mainly treats liver cancer (hepatocellular carcinoma), lung cancer, kidney cancer, and bone metastases. It is also being used for tumors that are challenging to treat surgically.

Minimally invasive procedures result in fewer complications, a shorter recovery time, targeted treatments that minimize damage to surrounding tissues, and they can be performed on patients who are not candidates for traditional surgery.

Related Market

Interventional Radiology Products Market

Read More

Oncology Market

Read More

Interventional Cardiology Devices Market

Read More
Partner

Our Clients